Profound Medical Announces Second Quarter 2019 Financial Results

TORONTO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today reported financial results for the three months ended June 30, 2019, and provided an update on its operations.

Recent Corporate Highlights

  • On April 4, 2019, Profound announced positive topline results from the TACT (TULSA-PRO® Ablation Clinical Trial) pivotal study designed to support its application to the U.S. Food and Drug Administration (“FDA” or the “Agency”) for 510(k) clearance to market TULSA-PRO® in the United States. In the TACT trial, all primary efficacy and safety endpoints, as well as all key secondary endpoints, were achieved.
  • On April 11, 2019, the Company hosted its first Analyst & Investor Day in New York, NY. The program featured presentations on TULSA-PRO® from key opinion leaders in the United States who have gained first-hand experience with the technology as investigators for the TACT trial and from current commercial users in Europe. In addition, leading global researchers and clinicians presented on both current and potential future applications for Sonalleve®.
  • On April 17, 2019, Profound announced that the first prostate cancer treatment using a first-of-its-kind installation combining its TULSA-PRO® system with Philips’ newest digital MR solution, the Ingenia Elition, was performed in Trier, Germany.
  • On May 5, 2019, Dr. Scott Eggener, Chief Investigator of the TACT study, and Director of the Prostate Cancer Program at the University of Chicago, shared detailed results from TACT during a late-breaking abstract presentation as part of the plenary session programming at the American Urological Association’s (“AUA”) 2019 Annual Meeting being held in Chicago, IL.
  • On May 6, 2019, Profound announced that its 510(k) application for TULSA-PRO® had cleared the FDA's acceptance review. The application is currently undergoing a substantive review by the Agency.
  • On June 13, 2019, the Company announced that all six nominees for its board of directors were elected and all matters put forward before shareholders were approved by the requisite majority of votes cast at its Annual and Special Meeting of Shareholders.
  • On July 9, 2019, Profound announced that it had sold its first TULSA-PRO® system in Japan to Hokuyu Hospital in Sapporo. The sale was made via Japan's Pharmaceutical and Medical Device Act’s expanded access program.  

“This was a pivotal quarter for Profound, marked by TACT’s compelling clinical trial data, positive TULSA-PRO® and Sonalleve® user feedback from leading researchers and clinicians at our first Analyst & Investor Day event, the strong reception that TULSA-PRO® received at AUA, and the filing of our 510(k) application for TULSA-PRO® with the FDA,” said Arun Menawat, Profound’s CEO.

Summary Second Quarter 2019 Results

All amounts, unless specified otherwise, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting.

For the quarter ended June 30, 2019, the Company recorded revenue of $574,109, with $465,840 from the sale of products and $108,269 from installation and training services. While second quarter 2019 revenue increased approximately 169% from $213,343 in the same three-month period a year ago, the Company noted that its Q2-2019 sales levels were negatively impacted by the lag time between product ordering and shipment.

“Despite triple-digit percentage growth over the comparable period in 2018, revenue for the 2019 second quarter was still below our internal expectation. This was due to some unfortunate timing, as a Sonalleve® system order slipped into Q3,” commented Dr. Menawat. “Had this shipment been completed in Q2-2019, revenues would have been approximately $1.2 million. Fortunately, with the recognition of this revenue anticipated in the third quarter, along with our growing sales pipeline of both TULSA-PRO® and Sonalleve®  products, we remain very well positioned and expect increasing commercial traction throughout the remainder of 2019.”

The Company recorded a net loss for the three months ended June 30, 2019 of $5,844,134, or $0.05 per common share, compared to a net loss of $5,831,028, or $0.05 per common share, for the three months ended June 30, 2018. The increase in net loss was primarily attributed to an increase in research and development (“R&D”) expenses of $838,446, an increase in selling and distribution expenses of $41,644 and an increase in net finance costs of $30,181. This was offset by a decrease in general and administrative (“G&A”) expenses of $650,206 and an increase in gross profits of $242,959

Expenditures for R&D for the three months ended June 30, 2019 were higher by $838,446 compared to the three months ended June 30, 2018. Clinical trial costs, materials, share based compensation and salaries and benefits increased by $219,569, $294,225, $33,986, and $244,263, respectively. These increases were due to increased spending and testing for R&D and U.S. regulatory projects, analysis of TACT clinical data, options awarded to employees, increased R&D personnel and a $60,000 decrease in investment tax credits because of lower eligibility for refundable tax credits.  Offsetting these amounts were decreases in rent of $57,456 due to the adoption of IFRS 16 resulting in the recognition of lower rental costs. Depreciation expenses increased by $26,762 due to the adoption of IFRS 16 with the depreciation of the right-of-use assets.

G&A expenses for the second quarter of 2019 decreased by $650,206 compared to the three months ended June 30, 2018. Salaries and benefits, consulting fees and travel decreased by $386,996, $386,594 and $24,337, respectively due to no bonuses being awarded to management this quarter, lower G&A project initiatives and decreased travel to customer sites. These costs were offset by an increase in share based compensation of $111,817, due to options awarded to various employees. Depreciation expense increased by $59,759 due to the adoption of IFRS 16 with the depreciation of the right-of-use assets.

Liquidity and Outstanding Share Capital

As at June 30, 2019, the Company had cash of $20,493,470. 

As at August 14, 2019, Profound had an unlimited number of authorized common shares with 108,072,939 common shares issued and outstanding.

For complete financial results, please see our filings at and our website at

Conference Call Details

Profound Medical is pleased to invite all interested parties to participate in a conference call today, August 14, 2019, at 4:30 pm. ET during which time the results will be discussed.

Live Call: 1-877-407-9210 (Canada and the United States)
  1-201-689-8049 (International)
Replay: 1-919-882-2331
Replay ID: 50000

The call will also be broadcast live and archived on the Company's website at under "Webcasts" in the Investors section.

About Profound Medical Corp.

Profound develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO®, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities.

TULSA-PRO® is CE marked and commercially launched in key European and other CE mark jurisdictions. TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH).

In April 2019, Profound announced positive topline results from a multicenter, prospective clinical trial, TACT, which is expected to support its recent application to the FDA for 510(k) clearance to market TULSA-PRO® in the United States. 

Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, uterine fibroids and palliative pain treatment. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved.  Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
T: 647.872.4849

Profound Medical Corp.
Interim Condensed Consolidated Balance Sheet

  June 30,
 December 31,
Current assets    
Cash 20,493,470  30,687,183 
Trade and other receivables 2,934,283  2,686,112 
Investment tax credits receivable 480,000  480,000 
Inventory 3,611,346  3,631,623 
Prepaid expenses and deposits 161,685  434,871 
Total current assets 27,680,784  37,919,789 
Property and equipment 914,848  1,207,357 
Intangible assets 3,449,342  4,013,561 
Right-of-use assets 2,408,572  - 
Goodwill 3,409,165  3,409,165 
Total assets 37,862,711  46,549,872 
Current liabilities    
Accounts payable and accrued liabilities 2,339,451  3,912,350 
Deferred revenue 420,741  312,558 
Long-term debt 3,475,358  1,339,583 
Provisions 87,741  1,352,017 
Other liabilities 614,285  567,296 
Derivative financial instrument 152,423  98,203 
Lease liabilities 211,599  - 
Income taxes payable 164,079  297,353 
Total current liabilities 7,465,677  7,879,360 
Long-term debt 8,562,737  10,615,662 
Deferred revenue 658,026  379,044 
Provisions 45,162  49,319 
Other liabilities 432,545  1,000,153 
Lease liabilities 2,279,037  - 
Total liabilities 19,443,184  19,923,538 
Shareholders’ Equity    
Share capital 120,942,484  120,932,404 
Contributed surplus 17,208,040  16,756,294 
Accumulated other comprehensive loss (86,935) (28,703)
Deficit (119,644,062) (111,033,661)
Total Shareholders’ Equity 18,419,527  26,626,334 
Total Liabilities and Shareholders’ Equity 37,862,711  46,549,872 

Profound Medical Corp.
Interim Condensed Consolidated Statement of Loss and Comprehensive Loss

June 30,
June 30,

June 30,

June 30,
Products 465,840  170,931  1,813,621  543,425 
Services 108,269  42,412  236,276  46,253 
  574,109  213,343  2,049,897  589,678 
Cost of sales  244,066  126,259  777,422  357,334 
Gross profit  330,043  87,084  1,272,475  232,344 
Operating Expenses         
Research and development 3,186,355  2,347,909  5,864,101  4,864,690 
General and administrative 1,586,323  2,236,529  3,100,436  3,539,733 
Selling and distribution 1,154,869  1,113,225  625,524  2,060,127 
Total operating expenses 5,927,547  5,697,663  9,590,061  10,464,550 
Operating Loss 5,597,504  5,610,579  8,317,586  10,232,206 
Other income and expense        
Finance costs 337,220  313,606  651,905  633,569 
Finance income (110,790) (117,357) (252,671) (157,161)
  226,430  196,249  399,234  476,408 
Loss before tax 5,823,934  5,806,828  8,716,820  10,708,614 
Income taxes   20,200  24,200  54,000  60,600 
Net loss for the period 5,844,134  5,831,028  8,770,820  10,769,214 
Other comprehensive loss        
Item that may be reclassified to profit or loss        
Foreign currency translation adjustment - net of tax (11,843) 57,943  (58,232) 14,695 
Net loss and comprehensive loss for the period 5,832,291  5,888,971  8,712,588  10,783,909 
Loss per share         
Basic and diluted net loss per share  0.05   0.05   0.08   0.12 

Profound Medical Corp.
Interim Condensed Consolidated Statement of Cash Flows

  Six months
June 30,
 Six months
June 30,
Operating activities    
Net loss for the period (8,770,820) (10,769,214)
Adjustments to reconcile net loss to net cash flows from operating activities:    
Depreciation of property and equipment 257,299  284,167 
Amortization of intangible assets 564,219  564,219 
Depreciation of right-of-use assets 204,126  - 
Share-based compensation 456,427  476,931 
Interest and accretion expense 681,258  522,215 
Change in deferred rent -  20,670 
Deferred revenue 387,165  28,520 
Change in fair value of derivative financial instrument 54,220  - 
Change in fair value of contingent consideration (208,911) (24,546)
Changes in non-cash working capital balances    
Investment tax credits receivable -  (120,000)
Trade and other receivables (248,171) 3,227,089 
Prepaid expenses and deposits 63,186  (93,660)
Inventory 20,277  (1,144,721)
Accounts payable and accrued liabilities (1,612,144) (2,320,795)
Provisions (1,219,114) 151,263 
Income taxes payable (133,274) 62,089 
Net cash flow used in operating activities (9,504,257) (9,135,773)
Financing activities    
Issuance of common shares -  34,500,000 
Transaction costs paid -  (2,455,695)
Payment of other liabilities (16,203) (164,389)
Payment of long-term debt and interest (534,709) (1,953,822)
Proceeds from share options exercised 5,399  102,375 
Payment of lease liabilities (143,943) - 
Total cash (used in) from financing activities (689,456) 30,028,469 
Net change in cash during the period (10,193,713) 20,892,696 
Cash – Beginning of period 30,687,183  11,103,223 
Cash – End of period 20,493,470  31,995,919